The Influence of Peripheral Arterial Disease on Outcomes
A Pooled Analysis of Mortality in Eight Large Randomized Percutaneous Coronary Intervention Trials
Jacqueline Saw, MD, FRCPC*,
Deepak L. Bhatt, MD, FACC
,*,
David J. Moliterno, MD, FACC
,
Sorin J. Brener, MD, FACC
,
Steven R. Steinhubl, MD, FACC
,
A. Michael Lincoff, MD, FACC
,
James E. Tcheng, MD, FACC
,
Robert A. Harrington, MD, FACC
,
Maarten Simoons, MD, FACC||,
TingFei Hu, MS
,
Mobeen A. Sheikh, MD
,
Dean J. Kereiakes, MD, FACC¶ and
Eric J. Topol, MD, FACC
* Department of Medicine, Division of Cardiology, Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada
Department of Cardiovascular Medicine, the Cleveland Clinic Foundation, Cleveland, Ohio
Department of Cardiovascular Medicine, University of Kentucky, Lexington, Kentucky
Division of Cardiology, Duke University Medical Center, Durham, North Carolina
|| Department of Cardiology, Erasmus University, Rotterdam, the Netherlands
¶ Lindner Center and the Ohio Heart and Vascular Center at the Christ Hospital, Cincinnati, Ohio

View larger version (33K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 3 Multivariable analyses evaluating adjusted hazard ratio (HR) mortality outcomes for individual studies and pooled data at (A) 30 days, (B) 6 months, and (C) 1 year. CI = confidence interval; PAD = peripheral arterial disease.
|
|

View larger version (31K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 4 Subanalysis of 6 randomized percutaneous coronary intervention trials comparing glycoprotein (GP) IIb/IIIa inhibitor versus placebo, stratifying composite event rates (death, myocardial infarction, or target vessel revascularization) according to peripheral arterial disease (PAD) presence. RRR = relative risk reduction.
|
|
Copyright © 2006 by the American College of Cardiology Foundation.